In the early stage of drug discovery, traditional target-based high-throughput screening (HTS) technology has been extensively used in hit identification due to its high-speed, high-efficiency, and quantitative characteristics. However, the detection model cannot fully reflect the biological activity of the selected samples. Cell-based high-content screening (HCS) technology enables simultaneous screening of compounds with multiple targets and parameters and realizes a comprehensive evaluation of the druggability of a compound at the cellular level. Thus, it is increasingly becoming an indispensable technology in the process of drug development. Creative Biostructure provides automated, high-throughput, and high-resolution imaging HCS solutions for global customers with drug screening demand. In fact, our HCS system is a general technology platform for drug screening model building, candidate drug screening, lead optimization, and drug toxicity evaluation.